在脑瘤中准MAPK途径:机制和治疗机会
Dimitrios Vrachas1, Elisavet Kosma1, Angeliki-Ioanna Giannopoulou1
1Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers
|January 10, 2026
概括
线素激活蛋白激酶 (MAPK) 途径失调驱动许多中枢神经系统 (CNS) 瘤. MAPK 抑制剂具有前景,但面临诸如血脑屏障的透等挑战,需要新的策略来有效治疗脑瘤.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 中枢神经系统 (CNS) 瘤复杂且难以治疗.
- 线粒激活蛋白激酶 (MAPK) 信号通路在中枢神经系统瘤中经常发生变化.
- 这些变化驱动瘤生长,并影响治疗反应.
研究的目的:
- 审查中枢神经系统瘤中MAPK通路的改变.
- 评估MAPK抑制的治疗场景.
- 讨论在脑瘤中针对MAPK向治疗的挑战和未来方向.
主要方法:
- 对基因组数据和临床研究的文献综述.
- 对MAPK路径失调的当前知识的综合.
- 评估已批准和新兴的MAPK抑制剂和组合策略.
主要成果:
- 由突变 (例如,BRAF V600E) 和融合 (例如,BRAF-KIAA1549) 驱动的MAPK通路过活化,在质瘤和质神经元瘤中很常见.
- 向MAPK抑制剂显示出潜力,但面临限制,包括血脑屏障透和抵抗机制.
- 内异质性和瘤微环境带来了额外的挑战.
结论:
- 在各种中枢神经系统瘤中,MAPK信号传递是关键的驱动因素.
- 向疗法正在改变针对特定分子亚型的治疗方法.
- 克服治疗耐药性和改善药物输送是推动脑瘤中MAPK导向精准医学的关键.
相关概念视频
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


